PNC Financial Services Group’s Stemline Therapeutics, Inc. STML Stock Holding History

PNC Financial Services Group’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,500	Closed	-$23K	–	4339
2018 Q1	$23K	Buy	+1,500	New	+$23.4K	﹤0.01%	3381
2015 Q2	–	Sell	-400	Closed	-$6K	–	4809
2015 Q1	$6K	Buy	400 +200	+100%	+$3.06K	﹤0.01%	3981
2014 Q4	$3K	Hold	200	–	–	﹤0.01%	3716
2014 Q3	$2K	Hold	200	–	–	﹤0.01%	3723
2014 Q2	$3K	Hold	200	–	–	﹤0.01%	3461
2014 Q1	$4K	Sell	200 -1,000	-83%	-$24.3K	﹤0.01%	3338
2013 Q4	$24K	Buy	1,200 +1,000	+500%	+$26.7K	﹤0.01%	2755
2013 Q3	$9K	Hold	200	–	–	﹤0.01%	3300
2013 Q2	$5K	Buy	+200	New	+$3.19K	﹤0.01%	3292

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

PNC Financial Services Group's STML Position: Q2 2018 in Review

PNC Financial Services Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 1,500 shares — an estimated $23K sold.

PNC Financial Services Group first reported a position in STML in Q2 2013 and held it in 9 quarters. The position peaked at $24K in Q4 2013. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

PNC Financial Services Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
PNC Financial Services Group sold 1,500 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $23K.
PNC Financial Services Group first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
PNC Financial Services Group's Stemline Therapeutics, Inc. position peaked at $24K in Q4 2013.
91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on PNC Financial Services Group's 13F filing for Q2 2018, filed 10 Aug 2018.